Trials
Search / Trial NCT00002670

Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery

Launched by RADIATION THERAPY ONCOLOGY GROUP · Jun 9, 2004

Trial Information

Current as of March 16, 2025

Completed

Keywords

Stage Ii Squamous Cell Carcinoma Of The Lip And Oral Cavity Stage Iii Squamous Cell Carcinoma Of The Lip And Oral Cavity Stage Iv Squamous Cell Carcinoma Of The Lip And Oral Cavity Stage Ii Squamous Cell Carcinoma Of The Oropharynx Stage Iii Squamous Cell Carcinoma Of The Oropharynx Stage Iv Squamous Cell Carcinoma Of The Oropharynx Stage Ii Squamous Cell Carcinoma Of The Hypopharynx Stage Iii Squamous Cell Carcinoma Of The Hypopharynx Stage Iv Squamous Cell Carcinoma Of The Hypopharynx Stage Ii Squamous Cell Carcinoma Of The Larynx Stage Iii Squamous Cell Carcinoma Of The Larynx Stage Iv Squamous Cell Carcinoma Of The Larynx

ClinConnect Summary

OBJECTIVES: I. Evaluate locoregional control rates, patterns of first failure, and overall and disease-free survival in patients with advanced squamous cell carcinoma of the head and neck at high risk of locoregional recurrence who are treated postoperatively with concurrent cisplatin and radiotherapy. II. Compare the toxicity of concurrent chemoradiotherapy vs. radiotherapy alone in the postoperative setting.

OUTLINE: Randomized study. Arm I: Radiotherapy. Involved-field irradiation using Co60, 1-6 MV photons, or electrons. Arm II: Radiotherapy plus Single-Agent Chemotherapy. Irradiation ...

Gender

ALL

Eligibility criteria

  • DISEASE CHARACTERISTICS: Biopsy-proven squamous cell carcinoma of one of the following sites: Hypopharynx Larynx Oral cavity Oropharynx At least 1 of the following high-risk factors required: Histologic extracapsular nodal extension Histologic involvement of 2 or more regional lymph nodes Microscopically positive mucosal margins Complete resection of all visible and palpable disease Therapy must begin within 8 weeks of tumor-related surgery Bilateral resections may or may not be performed simultaneously Eligibility window begins with first definitive surgery Neck dissection not required for T4 N0, truly midline supraglottic tumors No tumors of the lip, nasopharynx, or sinuses No synchronous or concurrent head and neck tumors No evidence of distant metastasis Concurrent registration on Fixed Tumor Repository Study allowed
  • PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60%-100% Hematopoietic: WBC at least 3,500 Platelets at least 100,000 Hepatic: Not specified Renal: Creatinine clearance greater than 50 mL/min Other: No medical contraindication to protocol therapy No second malignancy within 5 years No pregnant or nursing women
  • PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to head and neck region Surgery: See Disease Characteristics

Trial Officials

Jay S. Cooper, MD, FACR, FACRO

Study Chair

NYU Langone Health

James N. Endicott, MD, PA

Study Chair

H. Lee Moffitt Cancer Center and Research Institute

Julie A. Kish, MD, FACP

Study Chair

Josephine Ford Cancer Center

About Radiation Therapy Oncology Group

The Radiation Therapy Oncology Group (RTOG) is a leading clinical trial sponsor dedicated to advancing the field of radiation oncology through rigorous research and collaboration. Established to improve patient outcomes, RTOG conducts multicenter clinical trials that evaluate innovative radiation treatment techniques, assess the efficacy of combined modality therapies, and enhance quality of life for cancer patients. Committed to scientific excellence, RTOG fosters partnerships among academic institutions, healthcare providers, and industry stakeholders, ensuring that findings translate into clinical practice to optimize cancer care and improve survival rates.

Locations

Milwaukee, Wisconsin, United States

Tampa, Florida, United States

Atlanta, Georgia, United States

Indianapolis, Indiana, United States

Minneapolis, Minnesota, United States

Cleveland, Ohio, United States

Omaha, Nebraska, United States

Decatur, Georgia, United States

Peoria, Illinois, United States

Urbana, Illinois, United States

Des Moines, Iowa, United States

Kalamazoo, Michigan, United States

Saint Louis Park, Minnesota, United States

Hackensack, New Jersey, United States

Pretoria, , South Africa

Duluth, Minnesota, United States

Nashville, Tennessee, United States

Cedar Rapids, Iowa, United States

Toledo, Ohio, United States

Milwaukee, Wisconsin, United States

Evanston, Illinois, United States

Nashville, Tennessee, United States

Tulsa, Oklahoma, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials